Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06191133 · ClinicalTrials.gov registry record · Phase 1
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
A Phase 1 study of Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer, sponsored by Lindsay Ferguson, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06191133 is a Phase 1 study of Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer that is actively recruiting participants, run by Lindsay Ferguson, MD. The registered enrollment target is 24 participants, below the 267-participant average among 6 other Cervical Intraepithelial Neoplasia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06191133, a Phase 1 study of Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer, is actively recruiting participants, sponsored by Lindsay Ferguson, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.
Conditions Studied
Interventions
- RADIATION Chemoradiation
- DRUG Fenofibrate
- PROCEDURE Cervical Conization
- PROCEDURE Hysterectomy
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06191133
The ClinicalTrials.gov registry entry for NCT06191133 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 6 other Cervical Intraepithelial Neoplasia trials with a reported enrollment target (91% lower). The listed sponsor is Lindsay Ferguson, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cervical Intraepithelial Neoplasia appearing as the primary indexed condition, and to 4 interventions - of which Chemoradiation is the first listed.
NCT06191133 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06191133 about?
NCT06191133 is a clinical study titled "Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma". Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to under...
What is the current status of trial NCT06191133?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-11-20. Estimated completion is 2026-11-30.
What conditions does trial NCT06191133 study?
This clinical trial studies the following conditions: Cervical Intraepithelial Neoplasia, Invasive Cervical Cancer.
What interventions are being tested in trial NCT06191133?
The interventions under investigation include: Chemoradiation (RADIATION), Fenofibrate (DRUG), Cervical Conization (PROCEDURE), Hysterectomy (PROCEDURE).
Who is sponsoring clinical trial NCT06191133?
This trial is sponsored by Lindsay Ferguson, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06191133 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Intraepithelial Neoplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
COMPLETED · Phase 1
-
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
RECRUITING · Phase 2
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
A Novel, Low-Cost, Handheld 3D Imaging System for Improved Screening for Cervical Neoplasia in Resource-Limited Settings
ACTIVE NOT RECRUITING · NA
-
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
COMPLETED · Phase 2
-
A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.